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Abstract
Introduction: Diabetes mellitus exerts a detrimental effect on cerebral vasculature affecting both macrovasculature and
microvasculature. However, although ischaemic stroke is typically included among macrovascular diabetic complications,
it is frequently omitted from microvascular diabetic complications. We aimed to compare the proportion of large-artery
atherosclerotic and small-vessel occlusion strokes among diabetic stroke patients, explore their differences and
outcomes, and assess potential mechanisms which may determine why some diabetic patients suffer large-artery
atherosclerotic stroke whereas others suffer small-vessel occlusion stroke.
Methods:We pooled data of diabetic patients from four prospective ischaemic stroke registries (Acute Stroke Registry
and Analysis of Lausanne (ASTRAL), Athens, Austrian, and Helsinki Stroke Thrombolysis Registries). Stroke severity and
prognosis were assessed with National Institutes of Health Stroke Scale (NIHSS) and ASTRAL scores, respectively;
functional outcome with three-month modified Rankin score (0–2 considered as favourable outcome). Logistic-
regression analysis identified independent predictors of large-artery atherosclerotic stroke.
Results: Among 5412 patients, 1069 (19.8%) were diabetics; of them, 232 (21.7%) had large-artery atherosclerotic and
205 (19.2%) small-vessel occlusion strokes. Large-artery atherosclerotic stroke had higher severity than small-vessel
occlusion stroke (median NIHSS: 6 vs. 3, p< 0.001), worse prognosis (median ASTRAL score: 23 vs. 19, p< 0.001), and
worse three-month outcome (60.3% vs. 83.4% with favourable outcome, p< 0.001). In logistic-regression analysis,
peripheral artery disease (odds ratio: 4.013, 95% confidence interval: 1.667–9.665, p< 0.01) and smoking (odds ratio:
1.706, 95% confidence interval: 1.087–2.675, p< 0.05) were independently associated with large-artery atherosclerotic
strokes.
Conclusion: In the diabetic stroke population, small-vessel occlusion and large-artery atherosclerotic strokes occur
with similar frequency. Large-artery atherosclerotic strokes are more severe and have worse outcome than small-vessel
occlusion strokes. The presence of peripheral artery disease and smoking independently predicted large-artery athero-
sclerotic stroke.
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Introduction
Diabetes mellitus (DM) exerts a detrimental eﬀect on
cerebral vasculature aﬀecting both macrovasculature
(via atherosclerotic changes)1 and microvasculature
(via lipohyalinosis).2–5 However, although ischaemic
stroke is typically included among macrovascular dia-
betic complications (along with coronary artery disease
and peripheral artery disease), it is frequently omitted
from microvascular diabetic complications (along
with retinopathy, neuropathy, and nephropathy)
even by classic medical textbooks6–8 and health care
organisations.9,10
Also, there are only limited data about the
proportions of macrovascular (i.e. large-artery athero-
sclerotic (LAA)) and microvascular (small-vessel occlu-
sion (SVO)) strokes in the diabetic stroke population,
as well as about their characteristics like severity,
prognosis, and outcome. Finally, it is not clear why
some diabetics develop LAA strokes whereas others
develop SVO strokes.
The aim of the present study was to analyse a
large multicentre population of diabetic patients
with ischaemic stroke, compare the proportions of
LAA and SVO strokes, and explore their diﬀerences
with regards to baseline characteristics, prognosis,
and outcome. Also, we sought to identify the poten-
tial mechanisms which may explain why some dia-
betic patients develop LAA stroke while others
develop SVO.
Methods
We pooled data from four prospective stroke registries,
i.e. the Acute Stroke Registry and Analysis of
Lausanne (ASTRAL) registry,11 the Athens Stroke
Registry,12 the Austrian Stroke Registry,13 and the
Helsinki Stroke Thrombolysis Registry.14 Stroke was
deﬁned as a new syndrome of rapidly developing clin-
ical symptoms and/or signs of focal disturbance of cere-
bral function lasting longer than 24 h with no apparent
cause other than vascular origin, regardless of whether
infarction was evident on cerebral imaging.15 Stroke
pathophysiologic mechanism was classiﬁed according
to the Trial of Org 10172 in Acute Stroke Treatment
(TOAST) classiﬁcation.16 Stroke severity was evaluated
at admission with the National Institutes of Health
Stroke Scale (NIHSS) score. Stroke prognosis was eval-
uated with the ASTRAL score.17 Favourable func-
tional outcome was deﬁned as modiﬁed Rankin scale
(mRS) score 2 at 3 months and at 12 months (for the
two registries in which 12-month functional outcome
was available, i.e. ASTRAL registry and Athens
Stroke Registry). DM was deﬁned as fasting plasma
glucose >126mg/dl (7.0mmol/l), a 2-h value in the
oral glucose tolerance test >200mg/dl (11.1mmol/l),
a random plasma glucose concentration >200mg/dl
(11.1mmol/l) in the presence of symptoms, or when
already on oral antidiabetics or insulin treatment.18
In order to distinguish between poststroke hypergly-
caemia and newly diagnosed hyperglycaemia, we used
the HbA1c during hospitalisation as a criterion.
If HbA1c 6.5%, the patient was considered as previously
diabetic. If HbA1c< 6.5%, a diagnosis of poststroke
hyperglycaemia was reached.10 Small vessel disease was
diagnosed with either CT or MRI. Inclusion criteria
included previously independent patients presenting
within 24h after stroke onset (or last proof of well-being
in case of stroke of unknown onset). Patients with missing
data about the presence of diabetes, TOAST type, NIHSS
score, ASTRAL score, or functional outcome at three
months were excluded from the analysis.
The scientiﬁc use of each registry was approved by
appropriate authorities according to national and insti-
tutional legislation.
Statistical analysis
Variables are summarised as median (interquartile range
(IQR)) or absolute number and percentage. Categorical
variables were compared with the Pearson 2 test and
continuous with theMann–WhitneyU test for two inde-
pendent groups or the Kruskal–Wallis one-way analysis
of variance for more than two independent groups.
Logistic regression analysis was performed in the
subpopulation of diabetic patients with LAA stroke
or SVO to identify which parameters can independently
predict LAA strokes. We included all relevant param-
eters which were available in the registries, i.e. age, sex,
and the main cardiovascular risk factors, i.e. hyperten-
sion, dyslipidaemia, active or ex-smoking, coronary
artery disease, peripheral artery disease, previous
stroke, and previous transient ischaemic attack.
Associations are presented as odds ratios (ORs) with
95% conﬁdence intervals (CIs). All reported p values
were based on two-sided tests; level of statistical signiﬁ-
cance was set at 10% for the univariate analysis (to pre-
vent type II errors, i.e. false-negative associations) and
at 5% for all other tests. The Statistical Package for
Social Sciences (SPSS Inc. version 16.0 for Windows)
was used for all statistical analyses.
Results
Our dataset comprised four prospective stroke regis-
tries including 7022 patients. Among them, 1610
(22.9%) had incomplete data and were excluded from
the analysis. Among the 5412 (77.1%) patients (mean
age 68.7 13.9 years) who were ﬁnally included in the
analysis, 3178 (58.7%) were males, and mean NIHSS
was 9.0 7.8. The baseline characteristics of the
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excluded patients were similar to those of included
patients (58.8% males, mean age 66.9 13.6, and
mean NIHSS of 9.3 6.9). There were no signiﬁcant
diﬀerences among the four stroke registries with
regards to the patients’ age and sex distribution
(Table 1). The nondiabetic population (n¼ 4343,
80.2%) had similar gender (42.3% females) and age
distribution (median age: 71 years) with the diabetic
population.
The baseline characteristics of the diabetic patients
(n¼ 1069, 19.8%) are summarised in Table 2. Among
them, there were 232 (21.7%) LAA strokes and 205
(19.2%) SVO strokes (Table 1). LAA strokes were
more severe than SVO strokes (median NIHSS: 6
(IQR: 3–13) vs. 3 (IQR: 2–6), p< 0.001) and had a
less favourable prognosis (median ASTRAL score: 23
(IQR: 19–30) vs. 19 (IQR: 17–22), p< 0.001). Among
the 232 LAA stroke patients, 21 (9.1%) underwent car-
otid endarterectomy.
At 3 and 12 months follow-up, favourable functional
outcome was less frequent in patients with LAA stroke
compared to patients with SVO stroke (58.9 vs. 83.4%,
OR: 0.303 (95%CI: 0.192–0.476), p< 0.001) and (62.3
vs. 86.8%, OR: 0.272 (95%CI: 0.155–0.478), p< 0.001),
respectively. Similarly, mortality at 3 and 12 months
was lower in patients with SVO stroke compared to
patients with LAA stroke (1.5 vs. 9.9%, OR: 0.367
(95%CI: 0.200–0.676), p¼ 0.001) and (2.5 vs. 11.9%,
OR: 0.436 (95%CI: 0.251–0.757), p< 0.01), respect-
ively. In the three of the four included registries
(Helsinki registry excluded), the rate of stroke recur-
rence was 9.5% in patients with SVO stroke and
13.3% in patients with LAA stroke (OR: 0.83,
95%CI: 0.44–1.58, p¼ 0.58).
In the logistic regression analysis, peripheral artery
disease (OR: 4.013, 95%CI: 1.667–9.665, p< 0.01) and
smoking (OR: 1.706, 95%CI: 1.087–2.675, p< 0.05)
were independently associated with LAA strokes.
Discussion
The present study shows that in a diabetic ischaemic
stroke population, SVO and LAA strokes occur with
similar frequency. LAA strokes are more severe and
have worse outcome than SVO. The presence of per-
ipheral artery disease and smoking are associated with
higher risk that a diabetic will develop LAA stroke.
Similar results can be identiﬁed in previous studies
from diﬀerent ethnic populations. In a prospective
ischaemic stroke registry in Spain, the proportion of
diabetic patients with LAA and SVO stroke was 41.2
and 35.1%, respectively.19 Similarly, in the Nurses’
Health Study which was performed in the USA, the
incidence of patients with LAA stroke and SVO
stroke was 12 and 13 per 100,000 person-years, respect-
ively, in female diabetic patients.20 Also, in a sub-
analysis of the Young Cerebral Infarction Study in
China, the proportion of diabetic patients—which
may be up to 10% of all young strokes21—with LAA
and SVO stroke was 40.8 and 36.0%, respectively.22
The classic concept of ischaemic stroke as a macro-
vascular complication is based on the profound athero-
genic eﬀect of diabetes, which is mediated by
endothelial dysfunction and inﬂammation, dyslipide-
mia, increased oxidation and glycosylation, and trigly-
ceride enrichment of lipoproteins.23 However, diabetes
exerts a detrimental eﬀect on microvasculature as well,
which is mediated by direct glucose-mediated endothe-
lial damage, oxidative stress due to superoxide overpro-
duction, and production of advanced glycation
end-products and sorbitol, and leads to impaired endo-
thelial permeability and extravascular protein depos-
ition.24 Obviously, the pathophysiologic derangements
aﬀecting the micro- and macrovasculature run in par-
allel and explain why ischaemic stroke in diabetics can
be either a micro- or a macrovascular complication, as
suggested by the present study and others.25 Moreover,
the strong association between smoking and athero-
sclerosis26 explain our ﬁnding that smoking increases
the risk that a diabetic smoker will develop a LAA
stroke rather than a SVO stroke. Similarly, our ﬁnding
that patients with peripheral artery disease have a
higher risk for LAA stroke (rather than SVO) is related
to the widespread nature of atherosclerotic lesions in
these patients. Of course, we need to keep in mind that
like in the general population, ischaemic stroke in
Table 1. Basic characteristics of the included stroke registries (diabetic patients only).
Period of patient
registration N Female Age (years) SVO stroke LAA stroke
ASTRAL 2003–2013 413 151 (36.7%) 72.8 (63.3–79.8) 67 (16.2%) 75 (18.2%)
Athens 2000–2011 414 153 (37.0%) 71.0 (64.0–77.0) 93 (22.5%) 91 (22.0%)
Austrian 2007–2012 105 40 (38.1%) 72.0 (62.0–80.5) 32 (30.5%) 21 (20.0%)
Helsinki 1995–2010 137 52 (38.0%) 71.0 (64.0–77.0) 13 (9.5%) 45 (32.8%)
Total 1069 396 (37.0%) 71.9 (63.6–78.0) 205 (19.2%) 232 (21.7%)
SVO: small-vessel occlusion; LAA: large-artery atherosclerotic
110 European Stroke Journal 1(2)
diabetic patients may have diﬀerent causes such as car-
dioembolism, atherosclerosis of large arteries, small
vessel disease, and other rare causes. The fact that dia-
betic patients have increased risk for LAA strokes and
small-vessel disease infarcts compared to the general
population should not be received as that these patients
may not have strokes of other aetiologies.
The strengths of this study include the multicentre
nature of the study involving diﬀerent populations (i.e.
from central, northern, and southern Europe), the large
dataset, the common deﬁnitions used to describe stroke
characteristics (e.g. NIHSS score to describe
stroke severity and TOAST classiﬁcation to classify
stroke aetiology) as well as the prospective registration
of consecutive patients in the included registries which
minimises the possibility of selection bias. However,
one could argue that there is heterogeneity among stu-
dies given that the proportions of SVO and LAA
strokes in the Helsinki Stroke Thrombolysis Registry
deviate from the mean values of the overall dataset,
i.e. the proportion of SVO is almost half and the pro-
portion of LAA is almost 50% higher than the
Table 2. Baseline characteristics of diabetic stroke patients.
Characteristics
All strokes
(n¼ 1069)
SVO strokes
(n¼ 205)
LAA strokes
(n¼ 232) p-value
Demographics
Age (years) 71.9 (63.6–78.0) 69.1 (62.0–75.0) 69.0 (61.5–75.9) 0.802
Female gender 396 (37.0%) 61 (29.8%) 71 (30.6%) 0.874
Clinical and laboratory values on admission
NIHSS 6 (3–14) 3 (2–6) 6 (3–13) <0.001
SBP (mmHg) 160 (140–177) 160 (148–180) 160 (142–180) 0.507
Glucose (mmol/L) 9.0 (6.9–11.9) 9.2 (7.0–12.6) 9.4 (7.3–12.2) 0.774
ASTRAL score 23 (19–32) 19 (17–22) 23 (19–30) <0.001
Risk factors
Hypertension 885 (82.9%) 163 (79.9%) 191 (82.3%) 0.518
Atrial fibrillation 316 (29.6%) 7 (3.4%) 0 (0.0%) N/A
Smoking 250 (27.1%) 50 (26.3%) 73 (39.2%) 0.008
Dyslipidemia 679 (63.7%) 138 (67.6%) 155 (67.1%) 0.903
Coronary artery disease 1003 (18.6%) 34 (16.7%) 59 (25.4%) 0.028
Peripheral artery disease 276 (5.2%) 8 (3.9%) 29 (12.8%) 0.001
Imaging
Brain MRI 154 (35.2%) 89 (43.4%) 65 (28.0%) 0.001
Outcome at 3 months
mRS¼ 0–2 637 (59.6%) 171 (83.4%) 140 (60.3%) <0.001
mRS¼ 3–5 295 (27.6%) 31 (15.1%) 69 (29.7%)
Death 137 (12.8%) 3 (1.5%) 23 (9.9%)
Outcome at 12 months
mRS¼ 0–2 486 (60.5%) 138 (86.8%) 102 (64.2%) <0.001
mRS¼ 3–5 170 (21.2%) 17 (10.7%) 38 (23.9%)
Death 147 (18.3%) 4 (2.5%) 19 (11.9%)
Treatment
Intravenous thrombolysis 254 (23.8%) 27 (13.2%) 66 (28.6%) <0.001
No specific thrombolytic treatment 804 (75.4%) 177 (86.3%) 163 (71.2%)
TOAST classification
Large artery atherosclerosis 232 (21.7%) N/A 232 (100%) N/A
Cardioembolic 345 (32.3%) N/A N/A N/A
SVO 205 (19.2%) 205 (100%) N/A N/A
Rare causes 15 (1.4%) N/A N/A N/A
Undetermined 272 (25.4%) N/A N/A N/A
SVO: small-vessel occlusion; LAA: large-artery atherosclerotic; SBP: systolic blood pressure; mRS: modified Rankin scale; N/A: not applicable
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corresponding averages in the overall dataset. A plaus-
ible explanation for this ﬁnding is apparently that the
Helsinki registry includes only patients who were trea-
ted with thrombolysis; SVO strokes are generally mild
and, very frequently, their NIHSS is lower than 4 which
is frequently used as a lower threshold for thromboly-
sis11,27 or due to mild symptoms they arrive later than
the thrombolysis time window. Therefore, it seems
logical that many SVO strokes were not treated with
thrombolysis and therefore were not included in the
Helsinki Stroke Thrombolysis Registry leading to
under-representation of SVO strokes in this registry.
These considerations strengthen further our
conclusions that SVO and LAA strokes occur with
similar frequency in the diabetic population given
that the true proportion of SVO strokes may be even
higher.
On the other hand, this study is limited by the lack of
data about parameters which are related to the severity
of the underlying stroke risk factors (e.g. number of
pack-years of smoking, glycosylated haemoglobin, left
ventricular hypertrophy documented by echocardiog-
raphy or electrocardiography, evidence of retinopathy,
proteinuria, white matter changes in brain MRI,
carotid plaque, and intima-media thickness assessment)
which could provide additional insight in the underly-
ing pathophysiology and shed more light to the ques-
tion why some diabetics develop SVO whereas others
suﬀer LAA stroke. It would be of interest to see
whether the results apply to both type I and type II
diabetic patients; however, relevant information was
not available in this dataset. Also, we had a relatively
large proportion of patient with missing data due to our
methodological approach to work on a complete data-
set in order to avoid any imputation of missing data.
This may have introduced selection bias in the analysis;
however, the baseline characteristics of the excluded
patients were similar to those of the included patients.
In addition, data about stroke recurrence were not
available for all databases. Finally, small vessel disease
was diagnosed with CT or MRI together with clinical
evaluation including elements such as lack of cortical
symptoms, presence of typical lacunar syndromes, and
the TOAST classiﬁcation. CT imaging together with
clinical judgment for distinguishing SVD from other
causes is a standard approach. Still, this may have
introduced bias given that the two methods have diﬀer-
ent accuracy.
In conclusion, the present study shows that in the
diabetic stroke population, SVO and LAA strokes
occur with similar frequency. LAA strokes are more
severe and have worse outcome than SVO. The pres-
ence of peripheral artery and smoking are associated
with higher risk that a diabetic will develop LAA
stroke.
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